Results 21 to 30 of about 87,017 (286)
Kidney & Blood Pressure Research, 2013 Background: Treating non-diabetic proteinuric patients with advanced renal disease with an angiotensin-converting enzyme (ACE) inhibitor is still subject to discussion.
Charles Christian Adarkwah +3 more
doaj +1 more source
Dose response of ACE inhibitors: implications of the SECURE trial
Current Controlled Trials in Cardiovascular Medicine, 2001 The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE)
Lonn Eva
doaj +1 more source
Effect of angiotensin‐converting enzyme inhibition on cardiovascular adaptation to exercise training
Physiological Reports, 2022 Angiotensin‐converting enzyme (ACE) activity may be one determinant of adaptability to exercise training, but well‐controlled studies in humans without confounding conditions are lacking.
Tórur Sjúrðarson +13 more
doaj +1 more source
Folia Medica Indonesiana, 2017 BNP secreted by left ventricle as response to wall stress in patient with heart failure. Elevated concentration of NT-pro-BNP correlate with severity of heart failure across all stages of the condition and left ventricle ejection fraction in patient ...
Halla Hisan Hartoto +2 more
doaj +1 more source
Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
Drugs in Context, 2013 Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors are known to reduce proteinuria and have been the first-line agents in the management of diabetic nephropathy for the past 20 years.
Eva Vivian, Chelsea Mannebach
doaj +1 more source
PLoS ONE, 2014 About 8% of the adult population is taking angiotensin-converting enzyme (ACE) inhibitors to treat cardiovascular disease including hypertension, myocardial infarction and heart failure. These drugs decrease mortality by up to one-fifth in these patients.
Miklós Fagyas +13 more
doaj +1 more source
Kidney Research and Clinical Practice, 2013 Background: Angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) may induce acute kidney injury (AKI). The aim of this study was to evaluate the role of the resistive index (RI), which reflects renal artery resistance on ...
Eun Seok Kim +9 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background While Wilms tumor (WT) typically has a favorable prognosis, relapsed cases—especially those with high‐risk histology—remain therapeutically challenging after intensive frontline therapy. The combination of vincristine and irinotecan has demonstrated activity in pediatric solid tumors, and pazopanib, a multi‐targeted tyrosine kinase ...
Maria Debora De Pasquale +6 more
wiley +1 more source
Folia Medica Indonesiana, 2017 Heart failure (HF) is the final common stage of many diseases of the heart. NT-proBNP levels are increased in HF and correlate well with ventricular wall stress and severity of HF. Combination therapy with Bisoprolol and ACE-inhibitor decreases NT-proBNP
Reine Risa Risthanti +2 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Metabolic syndrome (MetS) is a common complication in survivors of childhood acute lymphoblastic and myeloid leukemia (AL), and a major risk factor for premature cardiovascular disease, type‐2‐diabetes, and metabolic dysfunction‐associated steatotic liver disease (MASLD).
Visentin Sandrine +10 more
wiley +1 more source